KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEquity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Gsk (GSK) Other Operating Expenses (2016 - 2025)

Historic Other Operating Expenses for Gsk (GSK) over the last 17 years, with Q3 2025 value amounting to $32.4 million.

  • Gsk's Other Operating Expenses rose 10743.85% to $32.4 million in Q3 2025 from the same period last year, while for Dec 2025 it was $178.6 million, marking a year-over-year increase of 10513.75%. This contributed to the annual value of -$2.0 billion for FY2024, which is 33316.23% down from last year.
  • Gsk's Other Operating Expenses amounted to $32.4 million in Q3 2025, which was up 10743.85% from $160.1 million recorded in Q2 2025.
  • Gsk's Other Operating Expenses' 5-year high stood at $890.3 million during Q4 2022, with a 5-year trough of -$2.0 billion in Q4 2024.
  • Its 5-year average for Other Operating Expenses is -$245.9 million, with a median of -$344.6 million in 2021.
  • As far as peak fluctuations go, Gsk's Other Operating Expenses tumbled by 120194.06% in 2021, and later skyrocketed by 27995.08% in 2022.
  • Over the past 5 years, Gsk's Other Operating Expenses (Quarter) stood at -$494.7 million in 2021, then skyrocketed by 279.95% to $890.3 million in 2022, then crashed by 179.61% to -$708.7 million in 2023, then crashed by 177.09% to -$2.0 billion in 2024, then surged by 101.65% to $32.4 million in 2025.
  • Its Other Operating Expenses stands at $32.4 million for Q3 2025, versus $160.1 million for Q2 2025 and -$13.9 million for Q1 2025.